Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Diabetic Nephropathy

In brief

The purpose of this study is to determine whether a new investigational drug, pirfenidone, will be an effective therapy for diabetic patients with kidney dysfunction. Our hypothesis is that administration of pirfenidone to type 1 and type 2 diabetic patients with advanced kidney disease will lead to preservation of kidney function.

Key facts

Study ID

NCT00063583

Run by

Sharma, Kumar, M.D.

People needed

77

Starts

2003-06-01

Expected to finish

2009-03-01

Last updated by the study team

2009-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) — Bethesda, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• The Center for Diabetic Kidney Disease at Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.